2 results
Approved WMOCompleted
The primary objective is to show a difference in responder rates between the study product (T4020) and the vehicle : a reduction of 50% or more in keratitis/ulcer area from baseline (inclusion visit = V2 = Day 0) assessed at Day 28 (Visit 6).
Approved WMORecruiting
To demonstrate the safety and efficacy of the SELUTION SLR* 014 DEB for treatment of bare-metal or drug-eluting in-stent restenosis (ISR).